News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Wilson_F_Perry_web_0.jpg)
Can SGLT2 inhibitors limit acute kidney injury in type 2 diabetes?
- Author:
- Mitchel L. Zoler, PhD
Contrary to the initial concerns that SGLT2 inhibitors might increase the risk of acute kidney injury, new data indicate that this complication is...
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
COORDINATEd effort boosts optimal therapy in patients with T2D and ASCVD
- Author:
- Mitchel L. Zoler, PhD
Cardiology clinics receiving educational and advisory guidance improved their treatment of patients with type 2...
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
EHR alerts boosted MRA prescribing to patients with HFrEF
- Author:
- Mitchel L. Zoler, PhD
Mineralocorticoid receptor antagonists are a foundational treatment for HFrEF, but often aren’t prescribed. EHR...
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Atorvastatin cut anthracycline cardiac dysfunction in lymphoma
- Author:
- Mitchel L. Zoler, PhD
A daily 40-mg dose of atorvastatin for 12 months significantly cut incident cardiac dysfunction in patients with...
News
Fewer than 10% of eligible type 2 diabetes patients get new, pricey drugs
- Author:
- Mitchel L. Zoler, PhD
Only 9% of eligible adults with T2D received treatment with an SGLT2 inhibitor or GLP-1 agonist in 2017-2020, in a new analysis.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Bonaca_Mark_CO_web.jpg)
Therapy app cut A1c, drug intensification in T2D
- Author:
- Mitchel L. Zoler, PhD
A smartphone app delivering cognitive behavioral therapy to adults with type 2 diabetes cut A1c while capping...
News
Longer diabetes duration links with increased heart failure
- Author:
- Mitchel L. Zoler, PhD
Prospective data from nearly 24,000 people with diabetes showed that longer diabetes duration significantly linked with an increased heart failure...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Ray_Kausik_K_AHA22_web.jpg)
Evolocumab’s LDL lowering surpassed inclisiran’s in ORION-3
- Author:
- Mitchel L. Zoler, PhD
Results from a crossover subgroup of 92 patients in ORION-3 documented evolocumab’s greater LDL-lowering efficacy, compared with inclisiran.
News
Fair access crucial for new diabetes/kidney disease drugs, say guidelines
- Author:
- Mitchel L. Zoler, PhD
A 2022 guideline for treating diabetes in people with chronic kidney disease highlighted the proven value of three underused drug classes and...
News
PPI use in type 2 diabetes links with cardiovascular events
- Author:
- Mitchel L. Zoler, PhD
Prospective data from almost 20,000 people with type 2 diabetes show that proton pump inhibitor use is linked with significantly more...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Verma_Subodh_ONT_AHA22_web.jpg)
Black HFrEF patients get more empagliflozin benefit in EMPEROR analyses
- Author:
- Mitchel L. Zoler, PhD
Empagliflozin trial data in patients with heart failure with reduced ejection fraction signal more benefit in Black, compared with White patients...
News
![Dr. Marc P. Bonaca, executive director of CPC Clinical Research and CPC Community Health, Aurora, Colo.](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Bonaca_Marc_P_COLO_ AHA22_web.jpg)
Cognitive behavioral therapy app lowers A1c in type 2 diabetes
- Author:
- Mitchel L. Zoler, PhD
People with type 2 diabetes who used a smartphone app for cognitive behavioral therapy had a significant drop in their A1c levels.
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Given the choice, T2D patients find their own best meds
- Author:
- Mitchel L. Zoler, PhD
People with type 2 diabetes who tried agents from three different classes of glucose-lowering drugs usually found one they liked most. It was...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/161319_Sapp_John_L_web_0.jpg)
CRT boosts heart failure survival in extended follow-up
- Author:
- Mitchel L. Zoler, PhD
Cardiac resynchronization extended survival during 5 extra years of follow-up of the RAFT study that compared CRT-D with ICD defibrillation alone...
News
FDA alert: ‘Substantial’ hypocalcemia risk with denosumab use in dialysis patients
- Author:
- Mitchel L. Zoler, PhD
The Food and Drug Administration sent an alert that it’s investigating an apparent link between the use of denosumab (Prolia) by patients on...